Shopping Cart
Remove All
Your shopping cart is currently empty
CYD-1-79
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T219174 Copy Product Info
🥰Excellent
CYD-1-79 is a selective positive allosteric modulator of the 5-HT2C receptor. It enhances serotonin (5-HT)-induced intracellular calcium release through a topologically unique allosteric site. CYD-1-79 significantly inhibits binding to dopamine D3 receptors, DAT, and α2A/α2B adrenergic receptors. In rodents, it modulates 5-HT2C receptor-mediated autonomic activity and synergizes with low-dose 5-HT2C receptor agonists. Additionally, CYD-1-79 reduces the susceptibility to relapse in self-administration models of psychoactive substances in rodents. It is applicable in neurological disorder research.
CYD-1-79
Cas No. 2220235-94-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CYD-1-79 is a selective positive allosteric modulator of the 5-HT2C receptor. It enhances serotonin (5-HT)-induced intracellular calcium release through a topologically unique allosteric site. CYD-1-79 significantly inhibits binding to dopamine D3 receptors, DAT, and α2A/α2B adrenergic receptors. In rodents, it modulates 5-HT2C receptor-mediated autonomic activity and synergizes with low-dose 5-HT2C receptor agonists. Additionally, CYD-1-79 reduces the susceptibility to relapse in self-administration models of psychoactive substances in rodents. It is applicable in neurological disorder research. |
| In vitro | CYD-1-79 (Compound 16) (1 pM-1 μM; 15 min) enhances serotonin-induced calcium release across various concentrations without causing a leftward shift. It does not modulate the 5-HT 2 A receptor-mediated intracellular calcium release in h5-HT 2 A R-CHO cells, indicating selectivity for the 5-HT 2 C receptor subtype. At 10 μM, CYD-1-79 shows no significant binding to the orthosteric sites of 5-HT receptor subtypes, including 5-HT 2 C, but exhibits notable inhibitory effects on the dopamine D 3 receptor, DAT, and α 2 A/α 2 B adrenergic receptors. |
| In vivo | CYD-1-79 (Compound 16), when administered intraperitoneally as a single dose of 5 mg/kg, significantly suppresses both locomotor and vertical activities in male Sprague-Dawley rats within the first 30 minutes post-administration; lower doses do not show this effect. At the same 5 mg/kg dose, CYD-1-79 allosterically enhances the motor inhibition effects of the 5-HT2C agonist WAY163909 via 5-HT2C receptor activation. Administered alone at doses of 0.125-1 mg/kg, CYD-1-79 partially substitutes for the discriminative stimulus effects of WAY163909, and when combined with a low dose of WAY163909 (0.5 mg/kg), it completely substitutes for these effects in trained male Sprague-Dawley rats. Additionally, CYD-1-79 (1 mg/kg; intraperitoneal injection; single dose) significantly reduces the reactivity of male Sprague-Dawley rats trained for self-administration of psychoactive substances to cues associated with these substances. |
| Molecular Weight | 356.54 |
| Formula | C20H40N2O3 |
| Cas No. | 2220235-94-7 |
| Smiles | C(NCC(CO)O)(=O)[C@@H]1C[C@H](CCCCCCCCCCC)CCN1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: CYD-1-79 in vivo | CYD-1-79 in vitro | CYD-1-79 formula | CYD-1-79 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.